Superworth

Neurocrine Biosciences profit margin NBIX

Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.

Net margin, 12 months
20.9%
Operating margin, 12 months
23.6%
Net margin on a year earlier
+7.0 pts
Peer median
26.3%

Over the twelve months to Jun 30, 2026, Neurocrine Biosciences kept 20.9% of its revenue as net profit, with an operating margin of 23.6% and a gross margin of 98.0%.

Five years earlier its net margin was 35.3%.

The median for 10 biotech stocks of a similar size is 26.3%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202516.7%21.6%98.2%
FY202414.5%24.2%98.6%
FY202313.2%13.3%97.9%
FY202210.4%16.7%98.4%
FY20217.9%9.0%98.7%
FY202038.9%15.6%99.0%
FY20194.7%9.2%n/a
FY20184.7%8.2%98.9%
FY2017−88.2%−81.3%99.2%
FY2016n/an/an/a
FY2015n/an/an/a
FY2014n/an/an/a
FY2013n/an/an/a
FY20129.5%2.7%n/a
FY201148.5%43.8%n/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY2620.9%+7.0 pts23.6%
Q1 FY2621.6%+8.9 pts25.4%
Q4 FY2516.7%+2.2 pts21.6%
Q3 FY2516.0%−1.3 pts20.5%
Q2 FY2513.9%−2.1 pts19.7%
Q1 FY2512.7%−6.0 pts20.5%
Q4 FY2414.5%+1.3 pts24.2%
Q3 FY2417.2%+6.5 pts25.8%
Q2 FY2416.0%+5.5 pts25.3%
Q1 FY2418.7%+14.6 pts23.4%
Q4 FY2313.2%+2.9 pts13.3%
Q3 FY2310.7%+6.5 pts11.4%

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

CompanyProfit margin
NBIXNeurocrine Biosciences20.9%
HALOHalozyme Therapeutics24.9%
EXELExelixis35.3%
TECHBIO-TECHNE15.0%
RGENRepligen5.3%
KRYSKrystal Biotech54.8%
INCYIncyte27.7%
UTHRUnited Therapeutics41.6%
ALNYAlnylam Pharmaceuticals16.8%
ONCBeOne Medicines10.7%
REGNRegeneron Pharmaceuticals27.9%
Peer median26.3%

Where Neurocrine Biosciences ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.